Janssen starts a new clinical trial as manufacturing issue is addressed

Janssen, a multinational pharmaceutical company owning the license of JNJ-64565111, a Hanmi Pharm’s biologic for the treatment of diabetes and obesity, will start a new clinical trial at the end of this year as the ‘manufacturing delay’ issue was addressed.

Hanmi Pharm(CEO Sae-Chang Kwon, Jong-Soo Woo) made a public announcement on the 9^th “Janssen has recently finished the Phase 1 clinical tr...